Company Profile
Neuroptek Corporation Inc. is a Canada-based manufacturer of portable ophthalmic and neuro-ophthalmic diagnostic devices, headquartered in Winnipeg, Manitoba, Canada. Founded in 2017 by Dr. Neda Anssari and Dr. Behzad Mansouri, the company operates as an independent, privately-held entity, serving neurologists, ophthalmologists, sports medicine physicians, and primary care providers in Canada, the United States, and global underserved markets.
Core Products ＆ Technologies
EyeMirage™ Smartphone Diagnostic System
• EyeMirage™ Headset: Portable dual-lens apparatus accommodating two smartphones for synchronized binocular eye tracking; features custom smartphone cases, dual-screen innovation, and synchronization mode for immersive visual testing
• EyeMirage™ Mobile App (Android/iOS): Companion software delivering Visual Acuity, Automated Visual Field, Colour Vision, Self-Paced Saccade, and Convergence tests; provides objective measures displayed as normal, borderline, or abnormal for concussion diagnosis
• Cloud-Based Data Transfer: Objective neurological and ophthalmic data collected and transferred to specialists through cloud-based systems for remote diagnosis and triage
Clinical Applications
• Concussion and Traumatic Brain Injury: Objective eye-movement assessment for sports medicine, emergency, and remote settings where immediate neurological expertise is unavailable
• Ophthalmic Disease Screening: Detection of glaucoma, optic nerve disease, retinal stroke, and cerebral stroke through visual function testing
• Tele-ophthalmology: Home-based and rural-community eye examinations replacing traditional clinic-bound perimetry and acuity equipment
Market Position ＆ Certifications
Neuroptek Corporation Inc. holds a pioneering position in the global portable smartphone-based ophthalmic diagnostic market, competing with Carl Zeiss Meditec (Humphrey Visual Field Analyzer) and Haag-Streit (Octopus perimetry) in traditional visual field testing, and Olleyes (VisuALL VR headset) in emerging portable diagnostics. Key strengths include:
• 8+ years of R＆D heritage in smartphone ophthalmic diagnostics
• Smartphone-native design: Leverages consumer smartphone cameras and computing power, eliminating the need for dedicated diagnostic hardware
• Regulatory compliance: FDA listed (May 2026); Health Canada Investigational Testing Authorization completed; ISO 13485:2016 and MDSAP certifications achieved
• Clinical validation: Key trial completed with St. Boniface Research Centre demonstrating equivalence to standard-of-care eye clinic tests; US Patent 11,596,302 granted March 2023
Corporate Timeline
2017 — Founded in Winnipeg, MB by Dr. Neda Anssari (neurologist) and Dr. Behzad Mansouri (neuro-ophthalmologist) to address healthcare inequities in remote eye and brain care
2021–2022 — Collaborated with Red River College Polytech ACE Project Space to develop EyeMirage app and refine clinical-standard testing algorithms
2023 — US Patent 11,596,302 granted for smartphone-based eye examination apparatus
2024–2025 — Completed clinical trials with St. Boniface Research Centre; presented positive results showing device equivalence to standard-of-care diagnostics
2026 — Achieved FDA listing, Health Canada ITA completion, ISO 13485 and MDSAP certifications (May); showcased at Hong Kong International Medical and Healthcare Fair (May 11–13, Booth 3E-D16); announced integration roadmap for retinal imaging and OCT technology
Target Markets ＆ Applications
• Sports medicine and concussion: Objective sideline and locker-room concussion assessment for hockey, football, and contact sports
• Rural and northern community care: Portable eye and neurological screening in underserved communities lacking opticians and specialized diagnostic equipment
• Global health and telemedicine: Low-cost vision and brain health screening for remote areas in Africa, India, and other underserved regions
Contact Information
Global Headquarters
Address: 3 St Anne＇s Rd, Winnipeg, Manitoba R2M 2X9, Canada
Parent Company
Neuroptek Corporation Inc. operates as an independent, privately-held entity with no parent company or publicly traded stock.
Website: neuroptek.com
Investor Relations: Private company; early investor and advisory board member Dave Richardson
